Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Qpex Biopharma logo — Focusing on Resistance in Antibiotic Development

Qpex Biopharma

Focusing on Resistance in Antibiotic Development

Founded 2018 United States San Diego, United States 29 employees Grant Total: $63.00M Biotechnology, Health Care

General Information

Company Name Qpex Biopharma
Founded Year 2018
Location United States San Diego, United States
Employees 29
Industries Biotechnology, Health Care
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Qpex Biopharma. To contact Qpex Biopharma, visit qpexbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Qpex Biopharma compare?

A PDF of Qpex Biopharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Qpex Biopharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Qpex Biopharma

Qpex Biopharma is a biotechnology company based in the United States, founded in 2018 and acquired by Shionogi, Inc in July 2023. The company's slogan "Focusing on Resistance in Antibiotic Development" reflects its mission to address drug resistance in infectious diseases. Qpex has a remarkable track record, having brought 4 antibiotic products to regulatory approvals over the past decade and has extensive experience in working with public-private partnerships, including Biomedical Advanced Research and Development Authority (BARDA), which led to the approval of the first antimicrobial drug product under that program in 2017. The company has received investments from New Enterprise Associates, Adams Street Partners, LYZZ Capital, Hatteras Venture Partners, and Stanford University Daper Fund, with the last investment being a $20.00M grant from Biomedical Advanced Research and Development Authority (BARDA) on 16 December 2019. Qpex is focused on creating innovative products and development strategies to overcome multi-drug resistance, aiming to deliver the right treatments to the right patients in the right settings. With its acquisition by Shionogi, Inc, Qpex is now part of the Shionogi Group Company, positioned for further growth and impact in the infectious disease sector.

Business keywords: Antimicrobial Resistance, Infectious Diseases, Drug Development, Antibiotics, Biopharmaceuticals, Antibiotic Resistance, San Diego, Public-Private Partnerships, Innovation in Antibiotic Development, Regulatory Approvals, Anti-Infective Therapies, Drug Discovery, Microbiology, Boron Chemistry

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $10.00M 1
Biomedical Advanced Research and Development Authority (BARDA)
30 May 2024
Grant $20.00M 1
Biomedical Advanced Research and Development Authority (BARDA)
16 Dec 2019
Series A $33.00M 5
New Enterprise Associates Adams Street Partners Hatteras Venture Partners
New Enterprise Associates, Adams Street Partners +3
22 Oct 2018

Qpex Biopharma Alternatives & Competitors

View All Alternatives
Qpex Biopharma vs
Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals United States

Fighting against antimicrobial resistance is at the core of our technology and our people.

Grant
14 employees
Biopharma, Biotechnology
Compare Qpex Biopharma vs Tetraphase Pharmaceuticals
Qpex Biopharma vs
Curza
Curza

Small molecule therapeutics R&D company focused on developing new drugs to combat antibiotic resista...

Venture round
17 employees
Biotechnology, Health Care
Qpex Biopharma vs
Bugworks Research Inc.
Bugworks Research Inc. India

Path breaking solutions to large unmet needs in Antimicrobial resistance (AMR) and immuno-oncology.

Venture round
46 employees
Biotechnology, Health Care
View all alternatives

FAQ About Qpex Biopharma

Focusing on Resistance in Antibiotic Development
Qpex Biopharma was founded in 2018.
Qpex Biopharma is headquartered in San Diego, United States.
Qpex Biopharma operates in Biotechnology and Health Care. Its work centres on Antimicrobial Resistance, Infectious Diseases, Drug Development and Antibiotics.
Qpex Biopharma has approximately 29 employees.
Qpex Biopharma has completed 3 funding rounds, raising a total of $63.00M. The latest funding stage is Grant.
Top alternatives and competitors to Qpex Biopharma include Tetraphase Pharmaceuticals, Curza, Bugworks Research Inc., Oragenics, Inc, AN2 Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Qpex Biopharma and Tetraphase Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Qpex Biopharma, https://bouncewatch.com/company/qpex-biopharma, updated 31 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout